Ibex Medical Analytics is hailing positive data from studies with U.S. partners on the impact of its artificial intelligence (AI)-powered cancer diagnostic platform Galen.
Diagnostic quality and efficiency findings regarding breast, prostate, and gastric cancers are being presented this week at the United States and Canadian Academy of Pathology (USCAP) annual meeting in Baltimore.
Ibex’s technologies, including AI-powered workflows and decision-support tools, are aimed at pathologists in everyday practice.
A study conducted at Brigham and Women’s Hospital and Champalimaud Foundation evaluated Galen Breast’s AI algorithm in identifying microinvasive carcinoma of the breast. It was found to be “highly accurate” in detecting microinvasive lesions, which can be challenging to identify and are often subject to either overdiagnosis or underdiagnosis that adversely affects treatment decisions, Ibex said in a statement.
“Galen Breast’s accuracy in detecting and classifying these minute tumors is a vital step forward in enhancing diagnostic confidence and providing oncologists with a comprehensive pathology diagnosis,” said Dr. Stuart Schnitt, chief of breast oncologic pathology at the Dana-Farber/Brigham Cancer Center and an investigator in the study.
In another study, researchers from Ohio State University (OSU) Wexner Medical Center report high accuracy for Galen Breast in detecting different types of breast cancer. The types included invasive and in situ carcinoma, as well as other pathologies, such as lobular neoplasia and microcalcifications across a diverse cohort of breast biopsies.
OSU Wexner will also present a study at USCAP’s annual meeting validating the performance of Galen Gastric in the diagnosis of gastric cancer, neuroendocrine tumors, H. pylori, and other gastric lesions, such as adenoma and low-grade dysplasia.
In addition, researchers at University of Pittsburgh Medical Center, assessed Galen Prostate’s performance in primary diagnosis of prostate biopsies. They found that the AI-powered solution was highly accurate in identifying and grading cancer in a live clinical setting, with negative and positive predictive values of 0.99.
Ibex said the study also included positive feedback from participating pathologists regarding Galen Prostate’s Gleason scoring, detection of perineural invasion, and automated measurement of tissue and tumor length.
Dr. Chaim Linhart, chief technology officer and co-founder of Ibex Medical Analytics, said the outcomes achieved in leading U.S. healthcare across various tissue types were outstanding, as well as helping clinicians to improve patient outcomes.
The Galen platform includes solutions for research use only (RUO) in the U.S. and not cleared by the U.S. Food and Drug Administration (FDA). Multiple Galen solutions are CE-marked and registered with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).
